GOBiolab Obtains Patent Rights for Obesity Treatment Composition Using Korean-Derived Strains
[Asia Economy Reporter Ji Yeon-jin] Gobiolab announced on the 4th that it has acquired a patent for a composition for the prevention and treatment of immune and metabolic diseases using strains independently discovered from Koreans.
Hot Picks Today
"KOSPI Surpassed 9,000, but May Fall Below 5,200 Next Year"...Expert Explains the Forecast
- In the Same Neighborhood, One Apartment Costs 2 Billion Won, Another 450 Million... What's Happening in Gangnam?
- "New Infections Sixteen Times Higher Than in 2019"... National Emergency Declared Over Spread of This Virus
- "I Thought I Lacked Willpower, But It Turns Out 'This Hormone' Is to Blame? [Experiment Note]"
- With Two Extra Days Added to Chuseok Holiday: "Pack Up, Let's Go Anywhere"... Domestic Travel Demand Surges
This patent utilizes a newly discovered Bacteroides vulgatus strain from Koreans to suppress obesity and metabolic diseases and has immune regulatory functions. It can be applied to products for the prevention, treatment, or improvement of metabolic diseases including obesity.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
